Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection

被引：0
|
作者：
Cody Orr
Wenjie Xu
Henry Masur
Shyam Kottilil
Eric G. Meissner
机构：
[1] Medical University of South Carolina,Division of Infectious Diseases
[2] Nanostring Technologies,Critical Care Medicine Department
[3] NIH Clinical Center,Division of Clinical Care and Research
[4] National Institutes of Health,Department of Microbiology and Immunology
[5] Institute of Human Virology,undefined
[6] University of Maryland School of Medicine,undefined
[7] Medical University of South Carolina,undefined
来源：
BMC Infectious Diseases | / 20卷
关键词：
Hepatitis C virus; Direct acting antiviral; Gene expression analysis; Sustained virologic response; Relapse;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
    Afdhal, Nezam
    Zeuzem, Stefan
    Kwo, Paul
    Chojkier, Mario
    Gitlin, Norman
    Puoti, Massimo
    Romero-Gomez, Manuel
    Zarski, Jean-Pierre
    Agarwal, Kosh
    Buggisch, Peter
    Foster, Graham R.
    Braeu, Norbert
    Buti, Maria
    Jacobson, Ira M.
    Subramanian, G. Mani
    Ding, Xiao
    Mo, Hongmei
    Yang, Jenny C.
    Pang, Phillip S.
    Symonds, William T.
    McHutchison, John G.
    Muir, Andrew J.
    Mangia, Alessandra
    Marcellin, Patrick
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20): : 1889 - 1898
  • [22] PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE
    Asselah, T.
    Zehnter, E.
    Agarwal, K.
    Sakai, Y.
    Yatsuhashi, H.
    Willems, B.
    Wright, D.
    Calinas, F.
    Calleja, J. L.
    Negro, F.
    Stern, J. O.
    Quinson, A. -M.
    Sha, N.
    Dorleacq, N.
    Schobelock, M.
    Jacobson, I. M.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S458 - S459
  • [23] STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
    Ferenci, Peter
    Asselah, Tarik
    Foster, Graham R.
    Zeuzem, Stefan
    Sarrazin, Christoph
    Moreno, Christophe
    Ouzan, Denis
    Maevskaya, Marina
    Calinas, Filipe
    Morano, Luis E.
    Crespo, Javier
    Dufour, Jean-Francois
    Bourliere, Marc
    Agarwal, Kosh
    Forton, Daniel
    Schuchmann, Marcus
    Zehnter, Elmar
    Nishiguchi, Shuhei
    Omata, Masao
    Kukolj, George
    Datsenko, Yakov
    Garcia, Miguel
    Scherer, Joseph
    Quinson, Anne-Marie
    Stern, Jerry O.
    JOURNAL OF HEPATOLOGY, 2015, 62 (06) : 1246 - 1255
  • [24] HCV-Genotype-2-Infection: Effectiveness and safety of sofosbuvir/Ribavirin-Therapy
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (01): : 14 - 14
  • [25] Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin
    Reau, N.
    Hamzeh, F. M.
    Lentz, E.
    Zhou, X.
    Jensen, D.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 (02) : 94 - 102
  • [26] RBV-FREE 12 WEEK TREATMENT OF HCV-RECURRENCE AFTER LIVER TRANSPLANTATION WITH SOFOSBUVIR/LEDIPASVIR IN GENOTYPE-1 PATIENTS
    Eurich, D.
    Globke, B.
    Teegen, E. M.
    Raschzok, N.
    Schott, E.
    Pratschke, J.
    TRANSPLANT INTERNATIONAL, 2016, 29 : 31 - 31
  • [27] Efficacy and Tolerability of a 12 week Course of Sofosbuvir-based HCV Antiviral Therapy without Ribavirin for Treatment of Recurrent HCV Genotype 1 Infection after Liver Transplantation
    Hassett, Molly S.
    O'Dell, Heather
    Raiford, David S.
    Truscott, Christie B.
    Chung, Chan Y.
    Schneider, Natasha J.
    Scanga, Andrew
    Perri, Roman
    Porayko, Michael K.
    HEPATOLOGY, 2015, 62 (06) : 1396A - 1397A
  • [28] High Rates of SVR in Treatment-Experienced Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/Sofosbuvir and Vedroprevir with or Without Ribavirin for 8 weeks
    Lawitz, Eric
    Poordad, Fred
    Hyland, Robert H.
    Liu, Lin
    Dvory, Hadas S.
    Pang, Phillip S.
    Brainard, Diana M.
    Gutierrez, Julio A.
    HEPATOLOGY, 2015, 62 : 337A - 337A
  • [29] Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
    Zeuzem, Stefan
    Berg, Thomas
    Gane, Edward
    Ferenci, Peter
    Foster, Graham R.
    Fried, Michael W.
    Hezode, Christophe
    Hirschfield, Gideon M.
    Jacobson, Ira
    Nikitin, Igor
    Pockros, Paul J.
    Poordad, Fred
    Scott, Jane
    Lenz, Oliver
    Peeters, Monika
    Sekar, Vanitha
    De Smedt, Goedele
    Sinha, Rekha
    Beumont-Mauviel, Maria
    GASTROENTEROLOGY, 2014, 146 (02) : 430 - +
  • [30] High Efficacy of Treatment with Sofosbuvir+GS-5816 ±Ribavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection
    Pianko, Stephen
    Flamm, Steven L.
    Shiffman, Mitchell L.
    Kumar, Sonal
    Strasser, Simone I.
    Dore, Gregory J.
    McNally, John
    Brainard, Diana M.
    Han, Lingling
    Doehle, Brian
    Mogalian, Erik
    McHutchison, John G.
    Reddy, K. Rajender
    Roberts, Stuart K.
    HEPATOLOGY, 2014, 60 : 297A - 298A
12345